Global In Situ Hybridization Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global In Situ Hybridization Market Research Report 2024
In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough, in the entire tissue, in cells, and in circulating tumor cells (CTCs). This is distinct from immunohistochemistry, which usually localizes proteins in tissue sections.
According to MRAResearch’s new survey, global In Situ Hybridization market is projected to reach US$ 705 million in 2033, increasing from US$ 545.2 million in 2022, with the CAGR of 3.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole In Situ Hybridization market research.
North America is expected to account for the largest share of the market in 2018. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global In Situ Hybridization market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Abbott Laboratories
Roche
Thermo Fisher Scientific
Merck
Agilent Technologies
Perkin Elmer
Danaher
Exiqon
Biogenex Laboratories
Advanced Cell Diagnostics
Bio Sb
Segment by Type
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization
Cancer Diagnosis
Immunology
Neuroscience
Cytology
Infectious Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The In Situ Hybridization report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global In Situ Hybridization market is projected to reach US$ 705 million in 2033, increasing from US$ 545.2 million in 2022, with the CAGR of 3.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole In Situ Hybridization market research.
North America is expected to account for the largest share of the market in 2018. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global In Situ Hybridization market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott Laboratories
Roche
Thermo Fisher Scientific
Merck
Agilent Technologies
Perkin Elmer
Danaher
Exiqon
Biogenex Laboratories
Advanced Cell Diagnostics
Bio Sb
Segment by Type
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization
Segment by Application
Cancer Diagnosis
Immunology
Neuroscience
Cytology
Infectious Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The In Situ Hybridization report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source